From the Journals

ICYMI: Canakinumab reduced risk of gout attacks


 

FROM THE ANNALS OF INTERNAL MEDICINE

Canakinumab, an interleukin-1–beta blocker, reduced the risk of a gout attack by 52% when administered every 3 months, according to a secondary exploratory analysis of data from the multicenter, randomized, double-blind, placebo-controlled CANTOS trial (NCT01327846). The results of this analysis were published Sept. 17 in the Annals of Internal Medicine (doi: 10.7326/M18-1167).

We covered this story before it was published in the journal. Find our conference coverage at the links below.


Next Article:

   Comments ()